Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer

Summary

This phase II trial is studying how well tandutinib works in treating patients who have undergone surgery for metastatic kidney cancer. Tandutinib may stop the growth of kidney cancer by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving tandutinib after surgery may kill any tumor cells that remain after surgery.

Timeline

Start

2006-11

Primary completion

2008-10

Completion

2008-12

Drugs

Indications